Aegerion Pharmaceuticals Initiates Phase 3 Clinical Trial in Japan to Evaluate Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
April 09, 2014 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 9, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel therapies for...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
April 07, 2014 16:05 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
March 07, 2014 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 7, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Observes Rare Disease Day
February 28, 2014 07:55 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Presentation at the Cowen and Company Healthcare Conference
February 27, 2014 16:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Announces Fourth-Quarter and Full-Year 2013 Financial Results
February 26, 2014 07:00 ET
|
Aegerion Pharmaceuticals, Inc.
-- Company Achieves 2013 Net Product Sales of $48.5 Million
-- 2014 Net Product Sales Expected to be Between $190 and $210 Million
-- Cash Flow Positive Operations Anticipated in the Second Half...
Aegerion Pharmaceuticals to Announce Fourth-Quarter and Full-Year 2013 Financial Results on Wednesday, February 26
February 13, 2014 08:30 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 13, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules Approved in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
February 10, 2014 08:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
February 07, 2014 16:00 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 7, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Announces Presentation at Leerink Global Healthcare Conference
February 06, 2014 16:40 ET
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...